Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

These meds are new enough that we need more time,” Straughn said. Wegovy, which is the weight-loss equivalent to the drug Ozempic, is approved by the FDA for use in kids as young as 12.